ERBB2 Mutations Associated with Solid Variant of High-grade Invasive Lobular Breast Carcinomas

Overview

Journal Oncotarget

Specialty Oncology

Date 2016 Sep 8

PMID 27602491

Citations 25

Authors

Gabrielle Deniziaut

Jean Christophe Tille

Francois-Clement Bidard

Sophie Vacher

Anne Schnitzler

Walid Chemlali

Laurence Tremoulet

Laetitia Fuhrmann

Paul Cottu

Roman Rouzier

Ivan Bieche

Anne Vincent-Salomon

Affiliations

Soon will be listed here.

Abstract

ERBB2 and ERBB3 somatic gain-of-function mutations, which may be targeted by anti-ERBB2 therapies, were reported by high-throughput sequencing studies in 1% and 2% of invasive breast cancers respectively. Our study aims to determine ERBB2 and ERBB3 mutations frequencies in grade 3 and/or ERBB2-positive invasive lobular breast carcinomas (ILC). All the 529 ILC surgically-excised registered at Institut Curie in the years 2005 to 2008 were reviewed. Thirty-nine grade 3 ERBB2-negative ILC and 16 ERBB2-positive ILC were retrieved and subjected to Sanger sequencing of the ERBB2 and ERBB3 activation mutation hotspots (ERBB2: exons 8, 17, 19, 20, 21; ERBB3: exons 3, 6, 7, 8). Among the 39 grade 3 ERBB2-negative ILC, six tumors were found to have at least one detectable ERBB2 activating mutation (incidence rate: 15%, 95%CI [4%-27%]). No ERBB2 mutation was found among the 16 ERBB2-positive ILC. No ERBB3 mutation was found in any of the 55 ILC. ERBB2 mutations were statistically associated with solid ILC features (p=0.01). Survival analyses showed no significant prognostic impact of ERBB2 mutations. Our study demonstrates that high grade ERBB2-negative ILC display a high frequency of ERBB2 mutations, and should be subjected to systematic genetic screening.

Citing Articles

Unique Molecular Alteration of Lobular Breast Cancer: Association with Pathological Classification, Tumor Biology and Behavior, and Clinical Management.

Zhang H, Peng Y Cancers (Basel). 2025; 17(3).

PMID: 39941785 PMC: 11816017. DOI: 10.3390/cancers17030417.

Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial.

Okines A, Curigliano G, Mizuno N, Oh D, Rorive A, Soliman H Nat Med. 2025; .

PMID: 39825152 DOI: 10.1038/s41591-024-03462-0.

Beyond Hormone Receptors: liquid biopsy tools to unveil new clinical meanings and empower therapeutic decision-making in Luminal-like metastatic breast cancer.

Pasto B, Vida R, Dri A, Foffano L, Della Rossa S, Gerratana L Breast. 2024; 79:103859.

PMID: 39708442 PMC: 11872398. DOI: 10.1016/j.breast.2024.103859.

Mutations Matter: Unravelling the Genetic Blueprint of Invasive Lobular Carcinoma for Progression Insights and Treatment Strategies.

Kontogiannis A, Karaviti E, Karaviti D, Lanitis S, Gomatou G, Syrigos N Cancers (Basel). 2024; 16(22).

PMID: 39594781 PMC: 11593237. DOI: 10.3390/cancers16223826.

The Diversity of Liquid Biopsies and Their Potential in Breast Cancer Management.

Keup C, Kimmig R, Kasimir-Bauer S Cancers (Basel). 2023; 15(22).

PMID: 38001722 PMC: 10670968. DOI: 10.3390/cancers15225463.

References

Fang Y, Jiang Y, Wang X, Yang X, Gao Y, Wang J . Somatic mutations of the HER2 in metastatic breast cancer. Tumour Biol. 2014; 35(12):11851-4. DOI: 10.1007/s13277-014-2414-y. View

Iwamoto T, Booser D, Valero V, Murray J, Koenig K, Esteva F . Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012; 30(7):729-34. DOI: 10.1200/JCO.2011.36.2574. View

Michaut M, Chin S, Majewski I, Severson T, Bismeijer T, De Koning L . Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancer. Sci Rep. 2016; 6:18517. PMC: 4700448. DOI: 10.1038/srep18517. View

Sastre-Garau X, Jouve M, Asselain B, Vincent-Salomon A, Beuzeboc P, Dorval T . Infiltrating lobular carcinoma of the breast. Clinicopathologic analysis of 975 cases with reference to data on conservative therapy and metastatic patterns. Cancer. 1996; 77(1):113-20. DOI: 10.1002/(SICI)1097-0142(19960101)77:1<113::AID-CNCR19>3.0.CO;2-8. View

Zabransky D, Yankaskas C, Cochran R, Wong H, Croessmann S, Chu D . HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proc Natl Acad Sci U S A. 2015; 112(45):E6205-14. PMC: 4653184. DOI: 10.1073/pnas.1516853112. View

Penault-Llorca F, Vincent-Salomon A, MacGrogan G, Roger P, Treilleux I, Valent A . [2014 update of the GEFPICS' recommendations for HER2 status determination in breast cancers in France]. Ann Pathol. 2014; 34(5):352-65. DOI: 10.1016/j.annpat.2014.08.018. View

Slamon D, Godolphin W, Jones L, Holt J, Wong S, Keith D . Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989; 244(4905):707-12. DOI: 10.1126/science.2470152. View

Wolff A, Hammond M, Hicks D, Dowsett M, McShane L, Allison K . Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2013; 138(2):241-56. PMC: 4086638. DOI: 10.5858/arpa.2013-0953-SA. View

Burgess A, Cho H, Eigenbrot C, Ferguson K, Garrett T, Leahy D . An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003; 12(3):541-52. DOI: 10.1016/s1097-2765(03)00350-2. View

10.

Perou C, Sorlie T, Eisen M, van de Rijn M, Jeffrey S, Rees C . Molecular portraits of human breast tumours. Nature. 2000; 406(6797):747-52. DOI: 10.1038/35021093. View

11.

Hortobagyi G . Trastuzumab in the treatment of breast cancer. N Engl J Med. 2005; 353(16):1734-6. DOI: 10.1056/NEJMe058196. View

12.

Jaiswal B, Kljavin N, Stawiski E, Chan E, Parikh C, Durinck S . Oncogenic ERBB3 mutations in human cancers. Cancer Cell. 2013; 23(5):603-17. DOI: 10.1016/j.ccr.2013.04.012. View

13.

Endo Y, Dong Y, Yoshimoto N, Asano T, Hato Y, Yamashita H . HER2 mutation status in Japanese HER2-negative breast cancer patients. Jpn J Clin Oncol. 2014; 44(7):619-23. DOI: 10.1093/jjco/hyu053. View

14.

Baselga J, Swain S . Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009; 9(7):463-75. DOI: 10.1038/nrc2656. View

15.

Grellety T, Soubeyran I, Robert J, Bonnefoi H, Italiano A . A clinical case of invasive lobular breast carcinoma with ERBB2 and CDH1 mutations presenting a dramatic response to anti-HER2-directed therapy. Ann Oncol. 2015; 27(1):199-200. DOI: 10.1093/annonc/mdv496. View

16.

Ng C, Martelotto L, Gauthier A, Wen H, Piscuoglio S, Lim R . Intra-tumor genetic heterogeneity and alternative driver genetic alterations in breast cancers with heterogeneous HER2 gene amplification. Genome Biol. 2015; 16:107. PMC: 4440518. DOI: 10.1186/s13059-015-0657-6. View

17.

Elston C, Ellis I . Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991; 19(5):403-10. DOI: 10.1111/j.1365-2559.1991.tb00229.x. View

18.

Ciriello G, Gatza M, Beck A, Wilkerson M, Rhie S, Pastore A . Comprehensive Molecular Portraits of Invasive Lobular Breast Cancer. Cell. 2015; 163(2):506-19. PMC: 4603750. DOI: 10.1016/j.cell.2015.09.033. View

19.

Garrett T, McKern N, Lou M, Elleman T, Adams T, Lovrecz G . The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors. Mol Cell. 2003; 11(2):495-505. DOI: 10.1016/s1097-2765(03)00048-0. View

20.

Greulich H, Kaplan B, Mertins P, Chen T, Tanaka K, Yun C . Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012; 109(36):14476-81. PMC: 3437859. DOI: 10.1073/pnas.1203201109. View